However, given that the off-target toxicity of MAGE-A3-specific aTCR for myeloma and melanoma in a clinical trial caused the death of some patients [111], a clinical trial of HIV-1-infected patients, NCT00991224, was suspended before any participant was infused with A2-SL9-specific aTCR-...
combinations of bNAbs with LRAs and/or ‘kill’ approaches need to be further tested. However, given that bNAbs are expensive and are unlikely used lifelong, these approaches can only
The Cardiff researchers say that the test could now be a 'game changer' in thetreatmentof chronic lymphocytic leukaemia (CLL). It also has the potential to change how other cancers, including myeloma andbreast cancer, are treated. While previous versions of the test had taken a week to proce...